Hexagon Nutrition Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Hexagon Nutrition Ltd filed with BSE on 18 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Hexagon Nutrition reported consolidated Q1 FY27 revenue of Rs 104.3 crore, up 43.2% year-on-year, with EBITDA of Rs 11.8 crore and profit after tax of Rs 8.1 crore. Management attributed the growth to volume increases across the premix, branded, and ESG segments, while noting that EBITDA margin declined due to higher raw material and freight costs linked to the West Asia crisis. Management also discussed capacity utilization, order book visibility, and investments in field force and distribution expansion into Tier 2 and Tier 3 cities.
Numbers mentioned
Consolidated revenue from operations: INR104.3 crores (Q1 FY27)
p. 3
“our consolidated revenue from operations stood at INR104.3 crores, registering a growth of 43.2% comparing with INR72.9 crores in Q1 of FY '26”
Nikhil Kelkar, page 3 of the filed PDF · View the filing
EBITDA: INR11.8 crores (Q1 FY27)
p. 3
“Our EBITDA stood at INR11.8 crores, representing a year-on-year growth of 17.3%”
Nikhil Kelkar, page 3 of the filed PDF · View the filing
Profit after tax: INR8.1 crore (Q1 FY27)
p. 3
“profit after-tax stood at INR8.1 crore, registering a growth of 25.1% over the corresponding quarter of the previous year”
Nikhil Kelkar, page 3 of the filed PDF · View the filing
Gross profit: INR45.8 crore (Q1 FY27)
p. 6
“Our gross profit for the quarter stood at INR45.8 crore, compared to INR34.1 crores in Q1 FY '26, representing a growth of 34.1%”
Soman Jana, page 6 of the filed PDF · View the filing
EBITDA margin: 11.3% (Q1 FY27)
p. 6
“Our EBITDA margin stood at 11.3% during the quarter compared with 13.8% in Q1 FY '26”
Soman Jana, page 6 of the filed PDF · View the filing
PAT margin: approximately 7.7% (Q1 FY27)
p. 6
“PAT margin stood at approximately 7.7% during the quarter”
Soman Jana, page 6 of the filed PDF · View the filing
Capacity utilization: 47% (Q1 FY27)
p. 7
“So overall, capacity-wise we have seen a volume growth this quarter, which representing around 47% of total capacity utilization at this stage.”
Mr. Soman, page 7 of the filed PDF · View the filing
Branded business revenue share: 28% (Q1 FY27)
p. 8
“branded business contributes for this quarter contributes around 28% of my total revenue”
Mr. Soman, page 8 of the filed PDF · View the filing
Premix business revenue share: 62% (Q1 FY27)
p. 8
“premix business gives me around 62% of the revenue”
Mr. Soman, page 8 of the filed PDF · View the filing
ESG/therapeutic segment revenue share: around 10% (Q1 FY27)
p. 8
“the remaining therapeutic segment that is the ESG contributes around 10%”
Mr. Soman, page 8 of the filed PDF · View the filing
Order book: INR100 crores (as of Q1 FY27 call)
p. 9
“our Q2 is very strongly supported by a strong order book of around INR100 crores”
Dr. Nikhil, page 9 of the filed PDF · View the filing
Inventory days: 142 days (Q1 FY27)
p. 12
“inventory days still stands around 142 days as on the Q1”
Mr. Soman, page 12 of the filed PDF · View the filing
Branded segment revenue growth: 22% (Q1 FY27 year-on-year)
p. 18
“the branded business has grown 22%, premix has grown 55%, and ESG has also grown 42% year-on-year”
Mr. Soman, page 18 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 20% to 25% · FY27
stated firmly by Mr. Soman
p. 8
“this year we will be keeping a same growth trajectory what we have posted last year, around 20% to 25% growth range we will be trying to keep”
Mr. Soman, page 8 of the filed PDF · View the filing
Branded/B2C revenue share — 35% of total revenue · next couple of years
stated as an aspiration by Dr. Nikhil
p. 9
“in the next couple of years we expect that to go to that 35% mark”
Dr. Nikhil, page 9 of the filed PDF · View the filing
ESG order pipeline revenue — INR75 crores to INR100 crores · remainder of FY27
stated conditionally by Mr. Vikram
p. 14
“we will be looking at around INR75 crores to INR100 crores. For the year.”
Mr. Vikram, page 14 of the filed PDF · View the filing
Capex for Nashik facility redevelopment — INR25 crores to INR30 crores · coming one year or one and a half years
stated firmly by Mr. Soman
p. 12
“we will be incurring a capex roughly around INR25 crores to INR30 crores in the coming one year or maybe one and a half years”
Mr. Soman, page 12 of the filed PDF · View the filing
Gross margin pressure easing — next two quarters
stated conditionally by Mr. Soman
p. 18
“we have increased our MRP from 10% to 15%. That will going to ease out the pressure in the gross margin the next two quarters”
Mr. Soman, page 18 of the filed PDF · View the filing
MRP increase on branded products impact — 10% to 15% MRP increase · Q2 onwards
stated firmly by Mr. Soman
p. 11
“Approx 10% to 15% we have increased our MRP. So that will see a impact in the Q2 onwards.”
Mr. Soman, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Top five export markets contribute 25-40% of export revenue.
Answered by Mr. Soman
Asked by Sparsh Bedmutha: What is the export revenue concentration among top markets?
p. 7
“it will be around 25% to 40% range of the initial top five countries we can mention”
Mr. Soman, page 7 of the filed PDF · View the filing
Capacity utilization is 47%, largely driven by the premix segment.
Answered by Mr. Soman
Asked by Sparsh Bedmutha: What is current capacity utilization and is it concentrated in one segment?
p. 7
“major of my capacity utilizations comes from the premix part, which contributes more than of my 50% revenue in the total segment”
Mr. Soman, page 7 of the filed PDF · View the filing
Gross margin contracted due to rising raw material costs linked to the West Asia crisis.
Answered by Mr. Soman
Asked by Akhilesh: Why did gross margin contract this quarter?
p. 10
“The major reason is the West Asia crisis where we have seen few of our critical raw materials in our segments in premix as well as branded has seen a rise in the cost.”
Mr. Soman, page 10 of the filed PDF · View the filing
Volume grew 25-40%, with limited price contribution except for MRP hikes on some branded products.
Answered by Mr. Soman
Asked by Akhilesh: What was the price vs volume split of revenue growth?
p. 10
“the volume has grown roughly around 25% to 40% for this quarter”
Mr. Soman, page 10 of the filed PDF · View the filing
Increase was due to higher freight costs from the geopolitical situation and strategic investment in sales, distribution and marketing.
Answered by Mr. Soman
Asked by Abhishek Maheshwari: What drove the sharp increase in other expenses?
p. 11
“The increase is on account of selling and distribution. Predominantly on the freight part. Our freight cost has increased due to this geopolitical impact.”
Mr. Soman, page 11 of the filed PDF · View the filing
Operating cash flow improved year-on-year as outstanding receivables from ESG and premix shipments were recovered.
Answered by Mr. Soman
Asked by Varun: How did operating cash flow perform and has cash conversion improved?
p. 12
“there was a large scale of shipments in the ESG and the premix segment which has improved this quarter. So major of our outstanding has been recovered.”
Mr. Soman, page 12 of the filed PDF · View the filing
Margin decline was driven by raw material cost pressure and freight costs, plus higher field force investment, though management expects easing over coming quarters.
Answered by Mr. Soman
Asked by Yash Parkar: What drove the meaningful EBITDA margin decline this quarter despite strong revenue growth?
p. 18
“the pressure is predominantly because of the gross margin issue that we have already discussed in one of the questions. And we believe that the critical raw material prices geopolitically has gone up and that has created the pressure.”
Mr. Soman, page 18 of the filed PDF · View the filing
Nashik runs at 55-60%, Chennai at 25-30%, Tuticorin at 35-40%, with Uzbekistan not yet significant.
Answered by Mr. Soman
Asked by Manasvini Mukherjee: What is the capacity utilization across the Nashik, Chennai, Tuticorin and Uzbekistan facilities?
p. 15
“Nashik we can say the capacity will be ranged roughly around 55% to 60%. And Chennai will be ranging around 25% to 30%. And Tuticorin will be around 35% to 40%.”
Mr. Soman, page 15 of the filed PDF · View the filing
Risks flagged
Rise in critical raw material costs due to the West Asia geopolitical crisis
p. 10
“The major reason is the West Asia crisis where we have seen few of our critical raw materials in our segments in premix as well as branded has seen a rise in the cost.”
Mr. Soman, page 10 of the filed PDF · View the filing
Increased freight costs due to geopolitical disruption impacting other expenses and PAT
p. 18
“Due to the West Asia crisis this freight cost has risen up which has added to the pressure in our PAT impact.”
Mr. Soman, page 18 of the filed PDF · View the filing
Tender-based nature of therapeutic nutrition/ESG business causes variable order flows between quarters
p. 5
“The tender-based nature of a part of this business means that order flows can vary between quarters.”
Vikram Kelkar, page 5 of the filed PDF · View the filing
Global impact of raw material cost increases expected to persist
p. 10
“this is a global impact, so we can expect that to remain, but the all the necessary steps are being placed into system right now”
Mr. Soman, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.
Continue reading
- Hexagon Nutrition Ltd: filed results and exchange announcements
- Q1 FY27 results for every company Parakho holds
More Q1 FY27 earnings calls, in alphabetical order